SG Americas Securities LLC Trims Position in Organogenesis $ORGO

SG Americas Securities LLC lowered its stake in shares of Organogenesis (NASDAQ:ORGO) by 48.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 188,878 shares of the company’s stock after selling 175,969 shares during the period. SG Americas Securities LLC owned 0.15% of Organogenesis worth $797,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of ORGO. Strs Ohio purchased a new stake in shares of Organogenesis during the 1st quarter valued at about $105,000. Assenagon Asset Management S.A. increased its stake in Organogenesis by 748.1% in the second quarter. Assenagon Asset Management S.A. now owns 2,857,904 shares of the company’s stock worth $10,460,000 after purchasing an additional 2,520,941 shares during the period. Farther Finance Advisors LLC purchased a new stake in Organogenesis in the 2nd quarter valued at about $35,000. HighMark Wealth Management LLC purchased a new stake in shares of Organogenesis in the second quarter valued at approximately $1,072,000. Finally, Ground Swell Capital LLC bought a new position in shares of Organogenesis during the 2nd quarter worth $39,000. 49.57% of the stock is owned by hedge funds and other institutional investors.

Organogenesis Stock Performance

NASDAQ ORGO opened at $3.71 on Wednesday. The company has a market cap of $470.84 million, a P/E ratio of -30.92 and a beta of 1.38. Organogenesis has a 1-year low of $2.61 and a 1-year high of $7.08. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.32 and a quick ratio of 2.88. The stock has a 50-day moving average of $5.01 and a two-hundred day moving average of $4.72.

Organogenesis (NASDAQ:ORGO) last issued its quarterly earnings results on Thursday, November 6th. The company reported $0.18 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.07 by $0.11. The company had revenue of $150.86 million during the quarter, compared to the consensus estimate of $134.10 million. Organogenesis had a negative net margin of 1.30% and a positive return on equity of 4.01%. As a group, analysts anticipate that Organogenesis will post -0.07 EPS for the current year.

Insider Buying and Selling

In related news, Director Glenn H. Nussdorf sold 200,000 shares of the business’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $5.14, for a total value of $1,028,000.00. Following the transaction, the director owned 2,565,591 shares in the company, valued at $13,187,137.74. The trade was a 7.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders have sold 500,000 shares of company stock valued at $2,620,120 in the last quarter. Insiders own 33.00% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on ORGO shares. Weiss Ratings reiterated a “sell (d+)” rating on shares of Organogenesis in a research note on Monday, December 29th. Wall Street Zen upgraded shares of Organogenesis from a “hold” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Finally, BTIG Research restated a “buy” rating and issued a $9.00 price objective on shares of Organogenesis in a research report on Friday, December 26th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $8.00.

Organogenesis Profile

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.